logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12599554 B1

PDFFull Text
Date of Patent:
Apr. 14, 2026

Filed:

Jul. 28, 2021

Pharmaceutical formulations comprising tadalafil

Applicant:

Kydes Pharmaceuticals, Llc, Rosedale, MD (US);

Inventor:

Stephen Kwaku Dordunoo, Rosedale, MD (US);

Assignee:

KYDES PHARMACEUTICALS LLC, , MD (US);

Attorney:

Jordan IP Law, LLC

Primary Examiner:

Sin J Lee

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/40 (2006.01); A61K 31/435 (2006.01); A61K 31/437 (2006.01); A61K 31/4525 (2006.01); A61K 31/48 (2006.01); A61K 31/485 (2006.01); A61K 31/4985 (2006.01); A61K 31/517 (2006.01); A61K 31/568 (2006.01); A61K 38/095 (2019.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61P 15/00 (2006.01); A61P 15/10 (2006.01);
U.S. Cl.
CPC ...
A61K 9/006 (2013.01); A61K 9/0034 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4875 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/40 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/4525 (2013.01); A61K 31/48 (2013.01); A61K 31/485 (2013.01); A61K 31/4985 (2013.01); A61K 31/517 (2013.01); A61K 31/568 (2013.01); A61K 38/095 (2019.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61P 15/00 (2018.01); A61P 15/10 (2018.01);
Abstract

Provided are stable, concentrated, and palatable solutions suitable for sublingual and/or transurethral administration containing tadalafil, with or without other active ingredients to address comorbidities, in a liquid vehicle or solvent selected from propylene carbonate, 2-pyrrolidone, dimethyl isosorbide, dimethyl acetamide, n-methyl-2-pyrrolidone, ethanol, water, oleic acid, and isopropyl myristate. The solutions have low irritancy for sublingual tissues and a-are compatible with commercial atomizers. The invention is further directed to methods of treating male erectile dysfunction and/or comorbidities by administering an effective amount of the pharmaceutical formulations comprising tadalafil, with or without other active ingredients, to a patient in need of such treatments.

Find Patent Forward Citations

Loading…